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          Opioid Use Disorder (OUD) is a chronic and relapsing psychiatric condition 
which is currently the leading cause of accidental death in the US. Symptoms of 
acute opioid withdrawal resemble a flu-like illness which is accompanied by a dys-
phoric state. Psychological comorbidities such as anxiety, depression, and disor-
dered sleep can persist for months or years, well into the abstinence period. These 
symptoms are thought to drive further opioid intake in order to alleviate this un-
pleasant internal state. Many differences in OUD have been documented between 
male and female patients, with females at higher risk for relapse and over-
dose.  This study sets out to characterize sex differences in symptoms and behav-
ioral adaptations in mice during early withdrawal. Using our moderate dose, three-
day precipitated withdrawal paradigm, we discovered significant effects of sex, 
time, and drug treatment on early withdrawal behaviors, locomotor activity, and gut 
motility in C57BL/6J mice. Here I will discuss previous methods of condensing be-
havioral phenotypes into one global withdrawal score, and propose a new method-
ology. This method increases the ability to detect nuanced effects and allows for 
more accurate translation across strain, sex, paradigm, and experimental context. 
Classification of opioid withdrawal-induced behavioral adaptations will allow for 
improved behavioral analysis of pharmacological manipulations, and investiga-
tions of brain circuitry involved in opioid withdrawal, as well as future screening of 
compounds with potential therapeutic benefit for the treatment of OUD.   
              
Despite their known addictive po-
tential, opioids such as morphine, oxyco-
done, and fentanyl are a widely prescribed 
group of analgesics. While opioids are 
highly efficacious for immediate pain relief, 
they are also associated with many ad-
verse effects. The opioid epidemic in 
America has largely been driven by the 
over-prescription of legal opioids, which 
are often the first exposure for individuals 
who go on to develop OUD (CDC). Toler-
ance, or decreased efficacy of drug treat-
ment over time, and opioid-induced hyper-
algesia, or increased pain sensitivity, can 
drive patients to escalate drug use1,2.  
Clinically, opioid withdrawal is ac-
companied by unpleasant physical and 
psychological symptoms which can drive 
disease relapse3,4. Our lab has developed 
a unique three-day paradigm as a clinically 
relevant animal model to study the effects 
of multiple bouts of opioid withdrawal in 
mice5–7. This paradigm makes use of a 
moderate dose of a general opioid receptor 
agonist and common clinical analgesic, 
morphine, over a shorter duration than 
other paradigms8,9. Naloxone, a competi-
tive opioid receptor antagonist, used clini-
cally to reverse opioid overdose, is admin-
istered to quickly precipitate withdrawal. 
We have previously demonstrated that this 
three-day paradigm produces early symp-
toms of withdrawal such as an increase in 
fecal boli production, escape jumping, paw 
 
tremors, and abnormal posture7. Addition-
ally, we demonstrate significant behavioral 
adaptations in protracted withdrawal that 
have been observed 6-weeks after drug 
exposure, reminiscent of those reported 
clinically, which include changes in anxi-
ety-like behavior, stress responsivity, sen-
sitization to subsequent morphine chal-
lenge, and social interaction deficits6. Inter-
estingly, we found sex differences in these 
features of protracted withdrawal6.  
 Much of the existing work investi-
gating opioid withdrawal has been con-
ducted exclusively in male rats. In order to 
study behavioral indications of altered in-
ternal state in our model of opioid with-
drawal, we must verify that behaviors of in-
terest are in fact indicative of changes due 
to morphine-naloxone pairing. In fact, this 
has been a challenge in clinical assess-
ment of withdrawal, with many distinct 
scales for scoring opioid withdrawal in 
adults10 and infants11. The ability to then 
condense these behaviors into one global 
withdrawal score is of value to our research 
as it would allow for validation of treatment 
efficacy and examination of individual dif-
ferences in response to morphine with-
drawal. Here I evaluate previously devel-
oped global scoring systems and propose 
a new approach that would better express 
the state of withdrawal as a whole, and al-
low for identification of nuanced effects, 
including those related to treatment, time, 
and sex at lower sample sizes. 
 
Behavioral Adaptations in Early Precip-
itated Withdrawal 
Validating and improving our model 
of opioid withdrawal is a continuous effort. 
Studying withdrawal in the context of sex 
differences provides new challenges, as 
classical withdrawal scales were devel-
oped using only male animals, specifically 
in male rats. Unfortunately, many differ-
ences in these withdrawal behaviors exist 
between these species and sexes that do 
not allow for easy translation. For example, 
we have not observed diarrhea or penile 
erection/ejaculation in our mice, especially 
not in females, so increased fecal boli pro-
duction and genital grooming have been 
used as proxies, with the assumption that 
these behaviors are equivalent. These as-
sumptions, however, have not been explic-
itly validated. Therefore, work is needed to 
probe for these sex differences and de-
velop a scoring system that reflects early 
withdrawal accurately in both male and fe-
male mice.  
To determine which behaviors ac-
curately reflect a state of morphine with-
drawal, mice were administered a subcuta-
neous injection of (0.9%) sterile saline (0.1 
ml/10g) or 10 mg/kg morphine (in sterile 
saline 0.1 ml/10 g). All mice then received 
 
Figure 1| Morphine administration protocol 
Mice were administered a subcutaneous injection of (0.9%) sterile saline (0.1 ml/10g) or 10 mg/kg mor-
phine (in sterile saline 0.1 ml/10 g). All mice then received a subcutaneous injection of 1 mg/kg naloxone 
(in sterile saline 0.1 ml/10 g) to precipitate withdrawal two hours later, and were observed for withdrawal 
symptoms. 
 
a subcutaneous injection of 1 mg/kg nalox-
one (in sterile saline 0.1 ml/10 g) to precip-
itate withdrawal two hours later. Freely be-
having mice were observed in an open field 
environment during the 10 minutes follow-
ing naloxone administration as previously 
described (Fig. 1)6,7. This paradigm has 
previously been shown to induce morphine 
dependence and subsequently withdrawal 
over the three-day administration period7.  
 
It was determined that escape 
jumps, paw tremors, abnormal posturing, 
and fecal boli production were significantly 
more pronounced in individuals of both 
sexes who had received morphine (Fig. 
2a-c).  Wet dog shakes and genital groom-
ing were not found to be significantly in-
creased during morphine withdrawal in our 
mice (Fig. 2d-e), and were therefore re-
moved from subsequent scoring. In fact, 
genital grooming was decreased in mor-
phine withdrawn mice, which we interpret 
as an anhedonic response and would ex-
pect to find an overall decrease in all types 
of grooming while mice experience this 
dysphoric internal state. Measures of gut 
motility were also taken, and  it was deter-
mined that fecal boli number increased in 
morphine treated mice in comparison to 
their non-withdrawn counterparts (Fig. 2f-
g). Furthermore, a time by drug treatment 
interaction was identified for weight 
wherein drug treated animals lost signifi-
cant body mass over the three-day with-
drawal period. Finally, locomotor behavior 
was also impacted by drug treatment, with 
withdrawn animals showing decreased 
time spent mobile and decreased average 
velocity during the 10-minute scoring pe-
riod as compared to control animals (Fig. 2 
h-i). In all, increases in escape jumping, 
paw tremors, abnormal posturing, and fe-
cal boli production, as well as decreased 
locomotion can be used to measure the ef-
fects of drug treatment on early withdrawal 
symptoms. Identification of these behav-
iors and confirmation of their validity as 
measures of morphine withdrawal in this 
paradigm will be significant for future ex-
periments examining the modulation of 
withdrawal by administration of various 
pharmacologic compounds.  
We have previously shown that 
early withdrawal related behaviors in-
crease over the three days of our with-
drawal paradigm7. As expected, many 
withdrawal-induced behaviors escalated 
over the three-day period, indicative of 
sensitization to the morphine-naloxone 
pairing. Paw tremors increased over time 
and exhibited a time x drug treatment inter-
action. Abnormal posturing, paw tremors, 
and fecal boli production also sensitized 
over the treatment period but did not show 
a time x drug treatment interaction. How-
ever, this increase is likely driven mainly by 
the morphine-treated group. Interestingly, 
wet dog shakes increased over time with-
out an effect of drug treatment, however 
this difference looks to be driven mainly by 
females. Additionally, time spent mobile 
and average velocity both decreased over 
the three-day treatment period, potentially 
as a result of a reduction in exploratory be-
havior due to habituation to the novel envi-
ronment. Since opioid use disorder (OUD) 
is a chronic and relapsing condition, it is 
important to validate that our animal model 
represents the cyclic and escalating nature 
of morphine dependence. 
Sex differences in OUD have been 
well documented 12–16, and some work has 
also been done to examine sex differences 
in rodent models of OUD14,17,18. Our lab 
has previously found sex differences in in-
hibitory (GABA) synaptic transmission in 
bed nucleus of the stria terminalis (BNST) 
24-hours following our three-day with-
drawal paradigm as well as sex differences 
 
in behavior 6 weeks into the protracted pe-
  
Figure 2| Morphine withdrawal alters behavior, locomotion, and gut motility  
Groups: Female Saline-Naloxone (FSN), Female Morphine-Naloxone (FMN), Male Saline-Naloxone 
(MSN), Male Morphine-Naloxone (MMN). a. Withdrawal-induced escape jumping [time: F (1.915, 65.13) 
= 2.932, sex: F (1, 34) = 1.062, treatment: F (1, 34) = 28.98, time x sex: F (2, 68) = 0.4386, time x drug 
treatment: F (2, 68) = 2.878, sex x drug treatment: F (1, 34) = 1.262, time x sex x drug treatment: F (2, 
68) = 0.6117.] Effect of drug treatment: ****p<.0001. b. Paw tremoring instances increase with morphine-
naloxone pairing [time: F (1.943, 66.07) = 16.11, sex: F (1, 34) = 0.6919, drug treatment: F (1, 34) = 
22.42, time x sex: F (2, 68) = 3.279, time x drug treatment: F (1, 34) = 0.7397, time x sex x drug treatment: 
F (2, 68) = 1.919.] Effect of drug treatment: ****p<.0001. Effect of time: ****p<.0001. Drug treatment x 
time interaction: ϕϕϕ p=0.0002. Sex x time interaction: Φ p=0.0437. c. Abnormal posturing increases in 
precipitated withdrawal [time: F (1.934, 65.76) = 6.974, sex: F (1, 34) = 10.35, drug treatment: F (1, 34) 
= 58.69, time x sex: F (2, 68) = 0.9133, time x drug treatment: F (2, 68) = 1.737, sex x drug treatment: F 
(1, 34) = 4.070, time x sex x drug treatment: F (2, 68) = 0.9546.] Effect of drug treatment: ****p <.0001. 
Effect of sex: **p=0.0028. Effect of time: **p=0.0020. d. Wet dog shake instance are unchanged but 
sexually dimorphic [time: F (1.866, 63.44) = 6.214, sex: F (1, 34) = 5.905, drug treatment: F (1, 34) = 
0.005423, time x sex: F (2, 68) = 0.9899, time x drug treatment: F (2, 68) = 1.024, sex x drug treatment: 
F (1, 34) = 0.005423, time x sex x drug treatment: F (2, 68) = 0.8150.] Effect of sex: *p=0.0205. Effect of 
time: **p=0.0042. e. Genital grooming decreases with drug treatment [time: F (1.924, 65.40) = 1.635, 
sex: F (1, 34) = 4.082, drug treatment: F (1, 34) = 16.53, time x sex: F (2, 68) = 2.659, time x drug 
treatment: F (2, 68) = 2.049, sex x drug treatment: F (1, 34) = 1.381, time x sex x drug treatment: F (2, 
68) = 3.220.] Effect of drug treatment: ***p=0.0003. Drug treatment x sex x time interaction:  π p=.0461. 
f. Fecal boli production increases in morphine withdrawal [time: F (1.857, 63.14) = 16.24, sex: F (1, 34) 
= 0.0001995, drug treatment: F (1, 34) = 22.92, time x sex: F (2, 68) = 0.04952, time x drug treatment: 
F (2, 68) = 0.2498, sex x drug treatment: F (1, 34) = 0.5188, time x sex x drug treatment: F (2, 68) = 
2.193.] Effect of drug treatment: ****p<.0001. Effect of time: ****p<.0001. g. Male morphine-treated mice 
lose weight in comparison to saline counterparts [time: F (1.776, 60.37) = 0.2372, sex: F (1, 34) = 1.053, 















































































































































































































riod6,7. When we compared early with-
drawal related behaviors in male and fe-
male mice, we found sex difference also 
exist at this timepoint. Paw tremors and 
posturing both showed an effect of sex, but 
not a sex x drug treatment interaction. It is 
possible that subtle differences exist in 
baseline behavior, or that naloxone treat-
ment, regardless of if the animal received 
morphine, is responsible for increased in-
stances in females. However, we hypothe-
size that this effect is driven by the mor-
phine treated animals who show a more 
dramatic difference between males and fe-
males. Additionally, paw tremors show a 
significant sex x time interaction, as the fe-
males reach peak expression of the behav-
ior earlier than their male counterparts. 
Further, genital grooming shows a signifi-
cant sex x time x drug treatment interac-
tion. This supports the hypothesis that 
grooming behavior may be an informative 
behavior, worthy of further investigation. 
Finally, because we had an a priori hypoth-
esis that there would be sex differences in 
weight loss, we ran statistical analysis  in-
dividually on males and females individu-
ally and found that male mice treated with 
morphine lost significantly more weight 
than their saline counterparts, while fe-
males showed no difference, consistent 
with our previous report7,19. 
Due to a historical bias in the rodent 
literature, where many experiments have 
been performed exclusively in male sub-
jects, it was important to develop a scoring 
system that would take sex differences in 
withdrawal presentation into account. Par-
ticularly, it needed to represent behaviors 
exhibited by both groups in order to be able 
to make fair comparisons between sexes 
so that we can determine if generalization 
of conclusions to both sexes is appropri-
ate. In this case we found that while our 
paradigm induces significant behavioral 
changes immediately after precipitation of 
withdrawal, nuanced differences in behav-
ioral expression exist between sexes. 
 
Re-examining global withdrawal scor-
ing 
There are several examples of scor-
ing systems developed for use in male rats 
that allow individual behaviors to be col-
lapsed into one global withdrawal score 7. 
These systems assigned a range for each 
behavior of interest with an associated 
point value, such that the total of the points 
would represent a global withdrawal score. 
However, in order to apply this method to 
a mouse model, it would have to be 
adapted in order to account for differences 
in types and frequency of behaviors be-
tween species. There is insufficient re-
search on inter-species naloxone-precipi-
tated morphine withdrawal differences to 
support this kind of manipulation, and 
would also require comparative assign-
ment of values to distinct behaviors based 
on their significance to the overall with-
drawal state, which would involve a great 
deal of speculation.  
Our group has previously used a 
method for condensed global scoring 
sex x drug treatment: F (1, 34) = 0.2153, time x sex x drug treatment: F (2, 68) = 0.4541.] A priori t-test 
for sex differences (-0.02617 ± 0.01147), effect of drug treatment: # p=0.0350. 3-way ANOVA, treatment 
x time interaction: ϕϕ p=0.0048. h. Time spent mobile decreases in morphine treated mice [time: F (2, 
30) = 56.16, sex: F (1, 15) = 0.1082, drug treatment: F (1, 15) = 19.07, time x sex: F (2, 30) = 0.7103, 
time x drug treatment: F (2, 30) = 0.6858, sex x drug treatment: F (1, 15) = 0.09068, time x sex x drug 
treatment: F (2, 30) = 1.073.] Effect of drug treatment: ***p=0.0006. Effect of time ****p<.0001. i. Average 
velocity decreases with morphine withdrawal [time: F (2, 30) = 4.947, sex: F (1, 15) = 0.6009, drug 
treatment: F (1, 15) = 5.646, time x sex: F (2, 30) = 1.069, time x drug treatment: F (2, 30) = 0.09265, 
sex x drug treatment: F (1, 15) = 1.262, time x sex x drug treatment: F (2, 30) = 0.03898.] Effect of drug 
treatment: *p=.0312. Effect of time: *p=.0139. For a-g: FSN and FMN n=9, MSN and MMN n=10. For h 





wherein each escape jump is worth 1 point, 
and the presence of other withdrawal-re-
lated behaviors is awarded 1 point 7. Using 
the previously developed method of con-
densing withdrawal scores (Fig. 3a), it 
would appear as though both male and fe-
male animals who received morphine ex-
hibit greater withdrawal associated behav-
ior when compared to their saline associ-
ated counterparts. These behaviors also 
sensitize over the three sessions of expo-
sure. This method of globalization as-
sumes that escape jumps are the most 
reliable measure of withdrawal as they are 
given considerably more weight than any 
other behavior. Indeed, escape jumps are 
a well-documented feature of precipitated 
withdrawal in mice, however many other 
behaviors contribute to the overall expres-
sion of withdrawal state. Consistent with 
our previous study7, no effect of sex was 
observed on number of withdrawal jumps, 
however there were significant sex differ-
ences in other symptoms measured. 
Therefore, by minimizing the contribution 
of other withdrawal behaviors, this system 
 
Figure 3| Understanding global withdrawal scoring using z-score system  
a. Combined withdrawal scores with previously used model [time: F (2, 68) = 3.556, sex: F (1, 34) = 0.8537, 
drug treatment: F (1, 34) = 32.03, time x sex: F (2, 68) = 0.5840, time x drug treatment: F (2, 68) = 2.808, 
sex x drug treatment: F (1, 34) = 1.541, time x sex x drug treatment: F (2, 68) = 0.5637.] Effect of drug 
treatment: ****p<0.0001. Effect of time: *p=.0340. b. Combined withdrawal scores using z-score system 
[time: F (2, 68) = 40.77, sex: F (1, 34) = 6.148, drug treatment: F (1, 34) = 396.7, time x sex: F (2, 68) = 
0.07988, time x drug treatment: F (2, 68) = 9.539, sex x drug treatment: F (1, 34) = 4.187, time x sex x 
drug treatment: F (2, 68) = 1.023.] Effect of drug treatment: ****p<0.0001. Effect of sex: *p=.0183. Effect 
of time: ****p<0.0001. Drug treatment x time interaction ϕϕϕ p=.0002. Drug treatment x sex interaction: δ 
p=.0485. c. Example of distribution of z-scores for a behavior (paw tremors) with effect of drug treatment. 






would be unable to capture nuanced ef-
fects and interactions, especially those in-
volving sex.  
As a solution to this escape jump bi-
asing in global withdrawal score, I propose 
that each of the behaviors determined to 
be indicative of morphine withdrawal be 
given weight based on the strength of the 
difference expressed (Fig. 3b). That is to 
say that if two groups are treated, one with 
morphine and the other with vehicle, then 
behaviors that are more modulated by drug 
treatment will exhibit greater variation be-
tween treatment groups (Fig. 3c) than ones 
with only a slight effect or no effect  (Fig. 
3d). In order to account for the differences 
in score range between behaviors, each 
subject’s score is represented as a stand-
ardized measurement of variance, in this 
case a z-score, or the number of standard 
deviations an individual animal’s score falls 
from the average of observed scores for 
that behavior across all groups and days of 
treatment. Individuals within a treatment 
group would naturally cluster together 
above or below the average if  the features 
of that group (sex and/or drug treatment) 
affected expression of that behavior. Addi-
tionally, the effect of time on behavioral 
score could also be accounted for with this 
method. If a behavior sensitizes over the 3-
day period, we would expect that on day 1 
scores would be below average, or receive 
a negative z-score, while on day 3 they 
would be above average, represented by a 
positive z-score. Examining two examples, 
these trends can be visually understood. A 
behavior, like wet dog shakes, that shows 
no significant effect of drug treatment pro-
duces a homogenized plot where mor-
phine and saline groups of respective 
sexes occupy the same space (Fig. 3d). In 
contrast, paw tremors show a robust effect 
of drug treatment, time, time x drug treat-
ment interaction, and sex x time interac-
tion. As these trends develop, treatment 
groups become more distinct and the plot 
becomes heterogeneous, representing 
these differences (Fig. 3c). When taken as 
a whole, weighted based on contribution to 
the altered internal state produced by our 
paradigm of opioid withdrawal, we can see 
that drug treatment, sex, and number of 
bouts of exposure all have interesting and 
intertwined relationships that are ex-
pressed through the behaviors we have 
identified here.  
 
Conclusions 
Here we demonstrate that there are 
many behavioral, locomotor, and gut-re-
lated effects of our paradigm of morphine 
withdrawal. In order to better understand 
one aspect of withdrawal, early behavior 
phenotypes, scores for individual behav-
iors can be condensed into a global with-
drawal score. By representing behavior 
scores as the number of standard devia-
tions from the mean of that behavior, each 
behavior is weighted by the extent to which 
expression is changed by an independent 
variable. This method can be easily 
adapted to different withdrawal manipula-
tions, as the behavior of control mice is 
used as a comparison, as opposed to as-
suming that mice will perform the same be-
haviors regardless of context. Providing 
set cutoffs for the assignment of point val-
ues, as has been done previously, only 
works within the context and conditions in 
which these values were originally as-
signed. Strain, species, sex, age, experi-
menter, environment, dose, rout of admin-
istration, time of testing, and cage environ-
ment can all change behavioral output. As 
an example, addition of a bedding to a box 
can encourage digging and reduce time for 
other behaviors being scored. Anecdotally, 
our lab has observed that administering 
morphine and naloxone in the same con-
text prevents escape jumping, whereas ad-
ministration of morphine in the home 
 
environment and naloxone in a novel one 
produces vigorous jumping. Mouse strains 
with high baseline anxiety or locomotion 
exhibit vastly different behavioral pheno-
types than their slower counterparts as I 
have observed working with strains of mice 
in the Collaborative Cross project.  
It is unlikely that when created, early 
withdrawal scoring systems were meant to 
be used as the definitive scale for with-
drawal behavior assessment, but rather 
were adopted in the absence of more ap-
propriate tools. Rather than assume that 
findings that do not reproduce original find-
ings are incorrect, this new, flexile method 
of using z-scores allows for the identifica-
tion of unanticipated findings and elabora-
tion on current knowledge. This new scor-
ing system will be used in the future to 
understand how individual variation in be-
havior corresponds with changes in brain 
activity, to compare the effects of norepi-
nephrine modulating drugs on opioid with-
drawal, and to screen compounds like ox-
ytocin for therapeutic potential. One limita-
tion to consider is that this global scoring 
system has only been tested in one model 
of opioid withdrawal. Subsequent experi-
ments will be performed to test this system 
in a paradigm of fentanyl drinking to estab-
lish translational value. Further work 
should be done to make sense of the inter-
esting changes in grooming behavior ob-
served as well as expand on our under-
standing of gut motility and locomotor 
tendencies as they relate to the dysphoria 


















All procedures were approved by the University of North Carolina Institutional An-
imal Use and Care Committee.  
 
Subjects 
Male and female, 8 to 12-week old C57/BL6 mice obtained from Jackson Labora-
tories were group or signally housed and habituated to their home-cage environment for 
2 weeks prior to all manipulations. Mice were housed on a 12:12 hour light-dark cycle and 
provided access to food and water ad libitum. Prior to behavioral experiments, mice re-
ceived two sessions of handling to minimize later stress, and allowed to recover undis-
turbed for one week. A subset of mice scored for withdrawal symptoms (20) were exposed 
to Ensure in their home cage for 3 hours on 4 consecutive days, one week prior to with-
drawal for a later experiment. The remaining were exposed to the scent of vanilla during 
withdrawal. These manipulations were necessary for subsequent experiments performed 
on these cohorts, but should not significantly impact data shown here.  
 
Morphine Withdrawal 
On withdrawal days, as previously described in Luster, et al. (2019) and Bravo, et 
al. (2020), mice received a subcutaneous injection of (0.9%) sterile saline (0.1 ml/10g) or 
10 mg/kg morphine (in sterile saline 0.1 ml/10 g). All mice then received a subcutaneous 
injection 1 mg/kg naloxone (in sterile saline 0.1 ml/10 g) in a distinct environment two 
hours later, and were observed for withdrawal symptoms over the following 10 minutes. 
A subset of these mice (20) were exposed to the scent of vanilla (in glycerol) contained 
in an adapted conical tube in the corner of the observation arena as described above. All 
mice where observed for symptoms 10 minutes following withdrawal, and videos were 
taken of the scent receiving animals, which was later assessed for locomotor activity us-
ing BehaviorCloud software.  
 
Statistics 
Withdrawal data were analyzed using 3-way ANOVA. Statistical significance was 
set at α = 0.05, and exact values are provided in figure legends. A priori t-tests for sex 
differences were conducted when appropriate. The statistical analyses for behavioral ex-
periments were performed using GraphPad Prism 9 software. Two mice were excluded 
from the study, one received a small needle stick in the foot during injections and the 
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